Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 65.74 |
| Average Volume (20 Days) | 262,015 |
Short Selling Information
The latest short interest is 1.03 million, so 2.77% of the outstanding shares have been sold short.
| Short Interest | 1.03M |
| Short Previous Month | n/a |
| Short % of Shares Out | 2.77% |
| Short % of Float | 5.00% |
| Short Ratio (days to cover) | 1.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -55.31M |
| Pretax Income | -53.81M |
| Net Income | -61.64M |
| EBITDA | n/a |
| EBIT | -55.31M |
| Earnings Per Share (EPS) | -$83.10 |
Full Income Statement Balance Sheet
The company has $15.14 million in cash and $16,000 in debt, with a net cash position of $15.12 million or $0.41 per share.
| Cash & Cash Equivalents | 15.14M |
| Total Debt | 16,000 |
| Net Cash | 15.12M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 13.09M |
| Book Value Per Share | -131.48 |
| Working Capital | 13.02M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$51.61 million and capital expenditures -$19,000, giving a free cash flow of -$51.63 million.
| Operating Cash Flow | -51.61M |
| Capital Expenditures | -19,000 |
| Free Cash Flow | -51.63M |
| FCF Per Share | -$1.38 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Veradermics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.18% |
| FCF Yield | -2.67% |
Analyst Forecast
The average price target for Veradermics is $78.33, which is 54.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $78.33 |
| Price Target Difference | 54.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |